Home Alzheimer’s Disease FDA Approves Additional Recommended Dose of Pembrolizumab in Adults

FDA Approves Additional Recommended Dose of Pembrolizumab in Adults

The FDA approved an additional recommended dose of pembrolizumab (Keytruda) across all adult indications, according to Merck, the agent’s manufacturer.

The accelerated approval is for 400 mg pembrolizumab every 6 weeks as a monotherapy or in combination with other agents, which is crucial given the current coronavirus disease 2019 (COVID-19) pandemic, according to Roy Baynes, MD, PhD.

“The important social distancing measures for COVID-19 have created a number of challenges for people with cancer, including keeping to planned treatment schedules,” Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said in a press release. “Today’s approval of an every 6-week dosing schedule for (pembrolizumab) gives doctors an option to reduce how often patients are at the clinic for their treatment.”

The approval is…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Recent Comments